In last trading session, Adaptive Biotechnologies Corp (NASDAQ:ADPT) saw 2.45 million shares changing hands with its beta currently measuring 1.55. Company’s recent per share price level of $8.37 trading at $0.1 or 1.21% at ring of the bell on the day assigns it a market valuation of $1.24B. That closing price of ADPT’s stock is at a discount of -6.93% from its 52-week high price of $8.95 and is indicating a premium of 72.76% from its 52-week low price of $2.28.

For Adaptive Biotechnologies Corp (ADPT), analysts’ consensus is at an average recommendation of Hold while assigning it a mean rating of 1.50. Splitting up the data highlights that, out of 11 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 6 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.29 in the current quarter.

Adaptive Biotechnologies Corp (NASDAQ:ADPT) trade information

Upright in the green during last session for gaining 1.21%, in the last five days ADPT remained trading in the green while hitting it’s week-highest on Tuesday, 02/18/25 when the stock touched $8.37 price level, adding 6.48% to its value on the day. Adaptive Biotechnologies Corp’s shares saw a change of 39.62% in year-to-date performance and have moved 7.31% in past 5-day. Adaptive Biotechnologies Corp (NASDAQ:ADPT) showed a performance of 22.91% in past 30-days.

Wall Street analysts have assigned a consensus price target of 14 to the stock, which implies a rise of 40.21% to its current value. Analysts have been projecting 5 as a low price target for the stock while placing it at a high target of 18. It follows that stock’s current price would jump 40.26% in reaching the projected high whereas dropping to the targeted low would mean a gain of 40.26% for stock’s current value.

Adaptive Biotechnologies Corp (ADPT) estimates and forecasts

This year revenue growth is estimated to rise 18.33% from the last financial year’s standing.

6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 44.08M for the same. And 6 analysts are in estimates of company making revenue of 48.56M in the next quarter. Company posted 41.87M and 43.19M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -1.51% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 13.09% while estimates for its earnings growth in next 5 years are of 27.30%.

Adaptive Biotechnologies Corp (NASDAQ:ADPT)’s Major holders

VIKING GLOBAL INVESTORS LP is the top institutional holder at ADPT for having 29.99 million shares of worth $108.58 million. And as of 2024-06-30, it was holding 20.3466 of the company’s outstanding shares.

The second largest institutional holder is RUBRIC CAPITAL MANAGEMENT LP, which was holding about 14.0 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.4971 of outstanding shares, having a total worth of $50.68 million.

On the other hand, ARK ETF Tr-ARK Genomic Revolution ETF and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 9.3 shares of worth $77.82 million or 6.30% of the total outstanding shares. The later fund manager was in possession of 4.19 shares on Sep 30, 2024 , making its stake of worth around $35.08 million in the company or a holder of 2.84% of company’s stock.